A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
A survey showing the number of 14-17 years olds who have tried the products has raised questions about their appeal to young people.
Top UK Advertising boss calls politicians to stop meddling in business and concentrate on creating wealth rather than spending cash
A touching note from a passenger thanking a pilot for getting her home safely in the wake of the Germanwings tragedy has gone viral.